Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We are maintaining our Neutral recommendation on lab chemical and life sciences company Sigma-Aldrich Corporation (SIAL - Analyst Report). While the company may gain from acquisitions and expansion initiatives, we remain on the sidelines considering currency headwind and continued challenges in its research business.

Why Maintained?

Sigma-Aldrich’s second-quarter 2013 revenues and adjusted earnings, reported on Jul 23, beat Zacks Consensus Estimates. The company saw organic sales gain across all business units in the quarter. While Sigma-Aldrich backed its sales growth guidance for 2013, it cut its earnings forecast citing incremental currency headwind.

Sigma-Aldrich’s significant investments in sales, marketing and R&D initiatives are generating demand for its products. The company is seeking to take advantage of country-specific opportunities by expanding its presence in high-growth emerging markets. It is actively expanding its foothold in the Asia-Pacific region, especially in the fast-growing emerging markets of India and China.

The BioReliance acquisition, which extended Sigma-Aldrich’s reach into the promising new market of biologic drugs, should add to its growth in 2013. The company also remains committed to offering returns to its shareholders through cash dividends and share repurchases. Sigma-Aldrich returned $108 million to its shareholders in first-half 2013 in form of dividends and share repurchases.

However, Sigma-Aldrich’s research business, especially with large pharmaceutical companies, is expected to continue to face challenges due to weak academic spending in the U.S. and Europe. The company expects uncertainty surrounding academic funding (in particular in the U.S. due to sequestration) to sustain through the balance of 2013.

Moreover, Sigma-Aldrich, which generates roughly 67% of its sales from the overseas markets, is highly exposed to currency headwinds. The company has reduced its earnings outlook for 2013 factoring in the incremental foreign exchange headwind. Earnings headwind is now expected to be 10 cents per share for the year versus 5 cents expected earlier.

Other Stocks to Consider

Other companies in the specialty chemical space with favorable Zacks Rank are Ferro Corp. (FOE - Snapshot Report), Quaker Chemical Corp. (KWR - Snapshot Report) and Sensient Technologies Corp. (SXT - Snapshot Report). All of them retain a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%